CTOs on the Move

Advion BioSciences, Inc.

www.advion.com

 
Advion BioSciences, Inc. was founded in 1993 based on the novel techniques developed within the Cornell University laboratory of Dr. Jack Henion, a leading researcher in the field of Liquid Chromatography/Mass Spectrometry (LC/MS).
  • Number of Employees: 0-25
  • Annual Revenue: $10-50 Million
  • www.advion.com
  • 19 Brown Rd
    Ithaca, NY USA 14850-1247
  • Phone: 607.266.0665

Executives

Name Title Contact Details

Similar Companies

Immune Pharmaceuticals

Immune Pharmaceuticals applies a personalized approach to treatment, developing novel, highly targeted antibody therapeutics to improve the lives of patients with inflammatory diseases and cancer. The Company’s lead product candidate, bertilimumab, is entering Phase II clinical studies for moderate-to-severe ulcerative colitis and bullous pemphigoid, with additional studies planned for Crohn’s disease and severe asthma. The Company is evaluating the use of its NanomAb® platform, a second generation antibody drug conjugate technology, with chemotherapeutics in order to enhance their safety and efficacy profiles by delivering the medicines directly to cancer cells. The Company’s growing oncology pipeline also includes proprietary antibodies and, clinical-stage small molecules that have been shown activity in a variety of solid tumors. Immune is headquartered in the U.S., with its primary research and development facilities in Israel.

Cellanyx

Cellanyx has developed proprietary live tumor cell phenotypic biomarker tests to improve cancer risk-stratification and allow informed clinical decision making. The Companys unique approach provides quantitative and actionable information based on analysis of thousands of live tumor cells. The Companys tests employ a microfluidic platform combined with machine vision and machine learning approaches to analyze phenotypic morphological, biochemical and biophysical markers. Cellanyx has demonstrated initial clinical proof-of-concept with its lead phenotypic test in prostate cancer. The initial clinical proof-of-concept study was conducted to demonstrate improved risk stratification in men with low and intermediate Gleason grade (6 and 7) disease and reduce the number of repeat biopsies. Furthermore, analysis of field samples (away from the suspicious core) demonstrated the potential value of Cellanyx phenotypic test as it was able to analyze the tumor microenvironment conditions and predict expected adverse pathology from samples that were not taken from the suspicious core. These new findings from the Cellanyx prostate test are transformative as it will reduce the errors in diagnosing cancers early due to sampling heterogeneity of prostate biopsies.

The Scientist

The Scientist is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Dale Commons Assisted Living

Dale Commons Assisted Living is a Modesto, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

PRA Health Sciences

At PRA Health Sciences, providing innovative solutions for our clients is what we do. Side by side with our clients, we strive to move drug discovery forward, helping develop life-saving and life-improving drugs. PRA has more than 10,000 employees working in 80+ countries providing comprehensive clinical development services across all phases. From full service clinical development to the pioneering Embedded Solutions model, PRA provides a broad spectrum of solutions that meet the demands of a diverse marketplace. As a top five CRO, we have worked on 100 plus marketed drugs across several therapeutic areas and conducted the pivotal or supportive trials that led to FDA and/or international regulatory approval of 50 plus such drugs.